| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Additional Risk Minimisation Measures for Medicinal Products in the European Union: A Review of the Implementation and Effectiveness of Measures in the United Kingdom by One Marketing Authorisation Holder
|
Agyemang, Elaine
|
|
2017
|
|
2 |
p. 101-112
|
artikel
|
| 2 |
Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies
|
Nakhoda, Shazia K.
|
|
|
|
2 |
p. 83-91
|
artikel
|
| 3 |
Addressing the Regulatory and Scientific Challenges with Generic Orally Inhaled Drug Products
|
Newman, Bryan
|
|
|
|
2 |
p. 93-102
|
artikel
|
| 4 |
Adverse Event Reporting Patterns of Marketing Authorization Holders, Healthcare Professionals and Patients in Japan: Lessons Learnt From the Human Papilloma Virus Vaccine
|
Inokuma, Yasuko
|
|
2018
|
|
2 |
p. 123-129
|
artikel
|
| 5 |
A Method for Retrieval of Adverse Event Terms in Clinical Trial Databases Using Standardised MedDRA Queries
|
Breder, Christopher D.
|
|
2016
|
|
2 |
p. 103-108
|
artikel
|
| 6 |
An Evaluation of the Effectiveness of Risk Minimization Measures for Tigecycline in the European Union
|
Frajzyngier, Vera
|
|
2017
|
|
2 |
p. 89-99
|
artikel
|
| 7 |
A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016
|
Ogar, Comfort Kunak
|
|
2019
|
|
2 |
p. 145-157
|
artikel
|
| 8 |
Artificial Intelligence Within Pharmacovigilance: A Means to Identify Cognitive Services and the Framework for Their Validation
|
Mockute, Ruta
|
|
2019
|
|
2 |
p. 109-120
|
artikel
|
| 9 |
A Transition to Targeted or ‘Smart’ Vaccines: How Understanding Commensal Colonization Can Lead to Selective Vaccination
|
Beitelshees, Marie
|
|
2018
|
|
2 |
p. 95-102
|
artikel
|
| 10 |
Attention Deficit/Hyperactivity Disorder among Adults in the United States
|
Sclar, David Alexander
|
|
2012
|
|
2 |
p. 97-101
|
artikel
|
| 11 |
Beyond the GAIN Act: Some Thoughts on Expediting Antibacterial Development to Address the Problem of Antimicrobial Resistance
|
Goldberger, Mark J.
|
|
2016
|
|
2 |
p. 71-78
|
artikel
|
| 12 |
Big Data in Pharmaceutical R&D: Creating a Sustainable R&D Engine
|
Tormay, Peter
|
|
2015
|
|
2 |
p. 87-92
|
artikel
|
| 13 |
Bioterrorism and the pharmaceutical industry
|
Snell, Noel J. C.
|
|
|
|
2 |
p. 63-64
|
artikel
|
| 14 |
Challenges in Administering a Clinical Trials Registry: Lessons from the Clinical Trials Registry-India
|
Pandey, Arvind
|
|
2013
|
|
2 |
p. 83-93
|
artikel
|
| 15 |
Characteristics of Post-Marketing Studies and their Contribution to Post-Marketing Safety Measures in Japan
|
Kanmuri, Kazuhiro
|
|
2014
|
|
2 |
p. 67-73
|
artikel
|
| 16 |
Considerations for Good Pharmacovigilance Outsourcing Practices
|
Furlan, Giovanni
|
|
2017
|
|
2 |
p. 75-80
|
artikel
|
| 17 |
Controlling Placebo Response in Drug Development: Lessons Learned from Psychopharmacology
|
Potter, William Z.
|
|
2014
|
|
2 |
p. 53-65
|
artikel
|
| 18 |
Correlation Between Elimination Parameters of Phenytoin and Carbamazepine in Patients with Epilepsy Receiving Both Drugs Concomitantly: A Preliminary Study
|
Panomvana, Duangchit
|
|
2017
|
|
2 |
p. 119-124
|
artikel
|
| 19 |
Critical Factors Shaping Strategy Development of an Innovative Medicine in Oncology
|
Krendyukov, Andriy
|
|
|
|
2 |
p. 103-112
|
artikel
|
| 20 |
Danish Physicians’ Views on the Appropriateness of the Involvement of Patients with Type 2 Diabetes in Regulatory Decision Making: A Qualitative Study
|
Sachs, Mikkel Lindskov
|
|
2019
|
|
2 |
p. 99-107
|
artikel
|
| 21 |
Defining Biological Subsets in Systemic Lupus Erythematosus: Progress Toward Personalized Therapy
|
Sinicato, Nailú Angélica
|
|
2017
|
|
2 |
p. 81-88
|
artikel
|
| 22 |
Drugs in Clinical Development for HIV: Summary and Table
|
|
|
2015
|
|
2 |
p. 105-111
|
artikel
|
| 23 |
Drugs in Clinical Development for Lung Cancer: Summary and Table
|
|
|
2013
|
|
2 |
p. 95-127
|
artikel
|
| 24 |
Drugs in Clinical Development for Multiple Sclerosis
|
|
|
2012
|
|
2 |
p. 103-112
|
artikel
|
| 25 |
Drugs in Clinical Development for Renal Cancer Summary and Table
|
|
|
2014
|
|
2 |
p. 75-84
|
artikel
|
| 26 |
Evaluation of the Effectiveness of Additional Risk Minimization Measures for Voriconazole in the EU: Findings and Lessons Learned from a Healthcare Professional Survey
|
Lem, Joanna
|
|
2019
|
|
2 |
p. 121-133
|
artikel
|
| 27 |
Extracting Knowledge from Failed Development Programmes
|
Wang, Yaning
|
|
2012
|
|
2 |
p. 91-96
|
artikel
|
| 28 |
Forum
|
|
|
2013
|
|
2 |
p. 129-136
|
artikel
|
| 29 |
Forum
|
|
|
2017
|
|
2 |
p. 125-138
|
artikel
|
| 30 |
Forum
|
|
|
2018
|
|
2 |
p. 149-167
|
artikel
|
| 31 |
Forum
|
|
|
2015
|
|
2 |
p. 113-125
|
artikel
|
| 32 |
Forum
|
|
|
2016
|
|
2 |
p. 117-128
|
artikel
|
| 33 |
Forum
|
|
|
2012
|
|
2 |
p. 117-127
|
artikel
|
| 34 |
Forum
|
|
|
2014
|
|
2 |
p. 85-91
|
artikel
|
| 35 |
Forum
|
|
|
2019
|
|
2 |
p. 159-173
|
artikel
|
| 36 |
Forum
|
|
|
|
|
2 |
p. 141-154
|
artikel
|
| 37 |
Global Access Programs: A Collaborative Approach for Effective Implementation and Management
|
Ainge, Debra
|
|
2015
|
|
2 |
p. 79-85
|
artikel
|
| 38 |
Immunogenicity Assessment of Biosimilars
|
Reinivuori, Tiina
|
|
2018
|
|
2 |
p. 103-121
|
artikel
|
| 39 |
Influence of Pharmaceutical Company Engagement Activities on the Decision to Prescribe: A Pilot Survey of UK Rare Disease Medicine Prescribers
|
Jandhyala, Ravi
|
|
|
|
2 |
p. 127-134
|
artikel
|
| 40 |
Journal Watch
|
|
|
2013
|
|
2 |
p. 137-149
|
artikel
|
| 41 |
Journal Watch
|
|
|
2012
|
|
2 |
p. 129-140
|
artikel
|
| 42 |
Journal Watch
|
|
|
2014
|
|
2 |
p. 93-103
|
artikel
|
| 43 |
Major Pharmaceutical Conferences and Courses
|
|
|
2014
|
|
2 |
p. 105-108
|
artikel
|
| 44 |
Major Pharmaceutical Conferences and Courses
|
|
|
2017
|
|
2 |
p. 139-141
|
artikel
|
| 45 |
Major Pharmaceutical Conferences and Courses
|
|
|
2018
|
|
2 |
p. 169-171
|
artikel
|
| 46 |
Major Pharmaceutical Conferences and Courses
|
|
|
2015
|
|
2 |
p. 127-130
|
artikel
|
| 47 |
Major Pharmaceutical Conferences and Courses
|
|
|
2016
|
|
2 |
p. 129-132
|
artikel
|
| 48 |
Major Pharmaceutical Conferences and Courses
|
|
|
2012
|
|
2 |
p. 141-143
|
artikel
|
| 49 |
Major Pharmaceutical Conferences and Courses
|
|
|
2013
|
|
2 |
p. 151-155
|
artikel
|
| 50 |
Major Pharmaceutical Conferences and Courses
|
|
|
2019
|
|
2 |
p. 175-177
|
artikel
|
| 51 |
Major Pharmaceutical Conferences and Courses
|
|
|
|
|
2 |
p. 155-157
|
artikel
|
| 52 |
Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases
|
Callréus, Torbjörn
|
|
2019
|
|
2 |
p. 83-88
|
artikel
|
| 53 |
One Programme, Four Stakeholders: An Overview of the Utilisation of Patient-Reported Outcomes in Intervention Development to Meet the Needs of Regulators, Payers, Healthcare Professionals and Patients
|
Reaney, Matthew
|
|
2015
|
|
2 |
p. 69-78
|
artikel
|
| 54 |
Pharmacovigilance in Nigeria: An Overview
|
Olowofela, Abimbola
|
|
2016
|
|
2 |
p. 87-94
|
artikel
|
| 55 |
Pharmacovigilance Rapid Alert System for Consumer Reporting (PRASCOR): A Look at Its Quantitative Contribution to Spontaneous Reporting in Nigeria from August 2012 to February 2017
|
Ogar, Comfort Kunak
|
|
2018
|
|
2 |
p. 131-141
|
artikel
|
| 56 |
Phase III CONCERT Trial of Latrepirdine
|
Sweetlove, Mel
|
|
2012
|
|
2 |
p. 113-115
|
artikel
|
| 57 |
Portfolio Decisions in Early Development
|
Herschel, Michael
|
|
2012
|
|
2 |
p. 77-84
|
artikel
|
| 58 |
Proposal for a New Stereochemically Informative Nonproprietary Drug Naming System
|
Gal, Joseph
|
|
|
|
2 |
p. 113-126
|
artikel
|
| 59 |
Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program
|
Speers, Marjorie A.
|
|
2019
|
|
2 |
p. 89-98
|
artikel
|
| 60 |
Quantitative Methods for Safety Monitoring of Rare Serious Adverse Events
|
Duke, Susan P.
|
|
2017
|
|
2 |
p. 113-118
|
artikel
|
| 61 |
RETRACTED ARTICLE: The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 6 Years After Approval
|
Martín-Merino, Elisa
|
|
2019
|
|
2 |
p. 135-144
|
artikel
|
| 62 |
Stem Cell-Based Toxicity Screening
|
Greenhough, Sebastian
|
|
2012
|
|
2 |
p. 85-89
|
artikel
|
| 63 |
Structured Qualitative Benefit-Risk Assessment to Inform Go/No-Go Decisions for Phase III Testing of Pharmaceutical Products
|
Wolka, Anne
|
|
2016
|
|
2 |
p. 79-85
|
artikel
|
| 64 |
The potential healthcare revolution
|
Sykes, Richard
|
|
|
|
2 |
p. 71-78
|
artikel
|
| 65 |
The Saudi Food and Drug Authority: Shaping the Regulatory Environment in the Gulf Region
|
Alsager, Sami
|
|
2015
|
|
2 |
p. 93-103
|
artikel
|
| 66 |
Trends in the Location of Phase 3 Clinical Trials Between 2008 and 2012: A Retrospective Review Utilizing ClinicalTrials.gov
|
Glass, Harold E.
|
|
2016
|
|
2 |
p. 109-115
|
artikel
|
| 67 |
Unregistered Medical Products Detected by Malaysia’s Pharmacy Enforcement Division During Routine Inspection: A Cross-Sectional Study among Selected Mainstream Medicines’ Retailers in the State of Sarawak
|
Ting, Chuo Yew
|
|
2018
|
|
2 |
p. 143-148
|
artikel
|
| 68 |
US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS)
|
Moore, Thomas J.
|
|
|
|
2 |
p. 135-140
|
artikel
|
| 69 |
Variation in Liver Biochemistries in Patients with Decompensated Cirrhosis: Implications for Assessing Drug-Induced Liver Injury in Clinical Trials
|
Jurek, Marzena
|
|
2016
|
|
2 |
p. 95-101
|
artikel
|
| 70 |
Will the EU Clinical Trials Regulation Support the Innovative Industry in Bringing New Medicines Faster to Patients?
|
Atzor, Sabine
|
|
2013
|
|
2 |
p. 75-82
|
artikel
|
Tijdschrift beschrijving